State Street’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$418K Buy
1,694,783
+339,200
+25% +$135K ﹤0.01% 3704
2025
Q4
$569K Hold
1,355,583
﹤0.01% 3646
2025
Q3
$913K Buy
1,355,583
+519,131
+62% +$280K ﹤0.01% 3531
2025
Q2
$453K Sell
836,452
-286,492
-26% -$170K ﹤0.01% 3634
2025
Q1
$736K Sell
1,122,944
-3,896,091
-78% -$4.13M ﹤0.01% 3498
2024
Q4
$5.12M Buy
5,019,035
+4,354,414
+655% +$7.96M ﹤0.01% 2965
2024
Q3
$576K Buy
664,621
+145,400
+28% +$107K ﹤0.01% 3572
2024
Q2
$186K Sell
519,221
-2,232,583
-81% -$1.21M ﹤0.01% 3844
2024
Q1
$1.84M Buy
2,751,804
+43,436
+2% +$31.5K ﹤0.01% 3303
2023
Q4
$1.47M Buy
2,708,368
+22,283
+0.8% +$10.3K ﹤0.01% 3394
2023
Q3
$1.61M Buy
2,686,085
+30,458
+1% +$32.6K ﹤0.01% 3411
2023
Q2
$3.45M Sell
2,655,627
-6,304,951
-70% -$8.61M ﹤0.01% 3173
2023
Q1
$15.8M Sell
8,960,578
-828,306
-8% -$2.36M ﹤0.01% 2384
2022
Q4
$30.7M Buy
9,788,884
+2,820,608
+40% +$10.9M ﹤0.01% 1945
2022
Q3
$34.1M Sell
6,968,276
-771,195
-10% -$3.96M ﹤0.01% 1867
2022
Q2
$32M Sell
7,739,471
-35,856
-0.5% -$155K ﹤0.01% 1924
2022
Q1
$45.2M Buy
7,775,327
+1,570,740
+25% +$9.34M ﹤0.01% 1824
2021
Q4
$46.5M Buy
6,204,587
+334,832
+6% +$2.91M ﹤0.01% 1853
2021
Q3
$52.9M Sell
5,869,755
-124,411
-2% -$1.23M ﹤0.01% 1764
2021
Q2
$71.8M Sell
5,994,166
-548,501
-8% -$6.21M ﹤0.01% 1570
2021
Q1
$82M Buy
6,542,667
+165,610
+3% +$2.23M ﹤0.01% 1384
2020
Q4
$99.5M Sell
6,377,057
-648,110
-9% -$7.59M 0.01% 1145
2020
Q3
$66.4M Buy
7,025,167
+536,249
+8% +$5.8M ﹤0.01% 1244
2020
Q2
$58.1M Buy
6,488,918
+1,641,150
+34% +$15.2M ﹤0.01% 1351
2020
Q1
$30.9M Buy
4,847,768
+33,142
+0.7% +$246K ﹤0.01% 1560
2019
Q4
$40.3M Sell
4,814,626
-204,450
-4% -$1.88M ﹤0.01% 1659
2019
Q3
$45.4M Sell
5,019,076
-328,832
-6% -$3.69M ﹤0.01% 1511
2019
Q2
$57.6M Sell
5,347,908
-504,733
-9% -$5.37M ﹤0.01% 1390
2019
Q1
$55.8M Sell
5,852,641
-57,511
-1% -$587K ﹤0.01% 1379
2018
Q4
$67.8M Sell
5,910,152
-602,475
-9% -$7.48M 0.01% 1155
2018
Q3
$110M Buy
6,512,627
+431,983
+7% +$6.57M 0.01% 1006
2018
Q2
$86.3M Buy
6,080,644
+1,543,693
+34% +$25.6M 0.01% 1135
2018
Q1
$86.2M Buy
4,536,951
+557,358
+14% +$11.9M 0.01% 1092
2017
Q4
$65.3M Buy
3,979,593
+1,088,783
+38% +$16.2M 0.01% 1264
2017
Q3
$43.4M Buy
2,890,810
+1,022,525
+55% +$11.3M ﹤0.01% 1472
2017
Q2
$16.4M Buy
1,868,285
+636,296
+52% +$4.08M ﹤0.01% 2125
2017
Q1
$6.41M Buy
1,231,989
+45,420
+4% +$182K ﹤0.01% 2580
2016
Q4
$3.61M Sell
1,186,569
-1,239,983
-51% -$4.52M ﹤0.01% 2854
2016
Q3
$11.2M Buy
2,426,552
+519,612
+27% +$2.64M ﹤0.01% 2128
2016
Q2
$11M Sell
1,906,940
-344,823
-15% -$2.2M ﹤0.01% 2166
2016
Q1
$13.6M Buy
2,251,763
+397,097
+21% +$2.38M ﹤0.01% 1985
2015
Q4
$16.9M Sell
1,854,666
-2,374,532
-56% -$18.3M ﹤0.01% 1833
2015
Q3
$23.9M Buy
4,229,198
+828,213
+24% +$6.83M ﹤0.01% 1641
2015
Q2
$37.7M Buy
3,400,985
+883,602
+35% +$11.4M ﹤0.01% 1434
2015
Q1
$39.5M Buy
2,517,383
+190,274
+8% +$2.94M ﹤0.01% 1378
2014
Q4
$35.4M Sell
2,327,109
-206,077
-8% -$2.5M ﹤0.01% 1407
2014
Q3
$27.3M Buy
2,533,186
+412,836
+19% +$5.39M ﹤0.01% 1513
2014
Q2
$32.4M Buy
2,120,350
+218,851
+12% +$3.15M ﹤0.01% 1472
2014
Q1
$34.4M Sell
1,901,499
-370,113
-16% -$7.13M ﹤0.01% 1415
2013
Q4
$31.6M Buy
2,271,612
+112,815
+5% +$1.3M ﹤0.01% 1456
2013
Q3
$22.6M Sell
2,158,797
-561,229
-21% -$5.57M ﹤0.01% 1618
2013
Q2
$21.2M Buy
+2,720,026
New +$23.7M ﹤0.01% 1599

Other funds holding SGMO

State Street's SGMO Position: Q1 2026 in Review

State Street increased its SANGAMO THERAPEUTICS INC (SGMO) stake by 25% in Q1 2026, buying an estimated $135K and bringing the position to 1,694,783 shares worth $418K. The position accounts for ﹤0.01% of the portfolio, ranked #3704.

State Street first reported a position in SGMO in Q2 2013 and has held it in 52 quarters since. The position peaked at $110M in Q3 2018. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • State Street held 1,694,783 shares of SANGAMO THERAPEUTICS INC worth $418K as of Q1 2026.
  • State Street bought 339,200 SANGAMO THERAPEUTICS INC shares in Q1 2026, an estimated $135K.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3704 holding.
  • State Street first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and has held it in 52 quarters since.
  • State Street's SANGAMO THERAPEUTICS INC position peaked at $110M in Q3 2018.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.